Tạp chí Tim mạch học Việt Nam

Chi tiết bài viết

Mô tả chi tiết bài viết

Trang chủ
CHUYÊN ĐỀ Số phát hành:

Can thiệp Động mạch vành qua da: Bóng, Stent và các loại giá đỡ

Phạm Mạnh Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Nguyễn Ngọc Quang: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Nguyễn Quốc Thái: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai; Phạm Nhật Minh: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Xuất bản: tháng 10 1, 2018
Views: 4
doi:10.58354/jvc.8485.2018.1121

Tóm tắt

Trong bài bình luận này, các thành tựu trong lĩnh vực can thiệp động mạch vành qua da được phác họa trong suốt quá trình phát triển 40 năm qua. Bài viết này đề cập đến những bước phát triển quan trọng, bao gồm những ca thông tim, chụp động mạch vành, nong động mạch vành bằng bóng đầu tiên cho đến các kỹ thuật ngày càng được tiêu chuẩn hóa, đặt stent động mạch vành và tối ưu hóa điều trị các thuốc chống đông máu đi kèm, stent phủ thuốc và bóng phủ thuốc cho đến các loại stent phủ thuốc kim loại hay làm bằng polyme tự tiêu sinh học

Từ khóa
Can thiệp động mạch vành qua da nong bóng đặt stent stent phủ thuốc bóng phủ thuốc stent tự tiêu sinh học thuốc chống đông thông tim chụp động mạch vành

Tài liệu tham khảo

1.
1. King SB 3rd (1998) The development of interventional cardiology. J Am Coll Cardiol 31:64b–88b.
DOI: doi.org/10.1016/s0735-1097(97)00558-5
2.
2. Wierny L, Plass R, Porstmann W (1974) Long-term results in 100 consecutive patients treated by transluminal angioplasty. Radiol- ogy 112:543–548.
DOI: doi.org/10.1148/112.3.543
3.
3. Kaltenbach M (2002) Evolution of interventional cardiology in Germany. J Interv Cardiol 15:33–39.
DOI: doi.org/10.1111/j.1540-8183.2002.tb01031.x
4.
4. Simpson JB, Baim DS, Robert EW, Harrison DC (1982) A new catheter system for coronary angioplasty. Am J Cardiol 49:1216–1222
DOI: doi.org/10.1016/0002-9149(82)90047-9
5.
5. Kaltenbach M (1984) The long wire technique - a new tech- nique for steerable balloon catheter dilatation of coronary artery stenoses. Eur Heart J 5:1004–1009.
DOI: doi.org/10.1093/oxfordjournals.eurheartj.a061601
6.
6. Bonzel T, Wollschläger H, Just H (1986) A new catheter system for the mechanical dilatation of coronary stenoses with exchangeable intracoronary catheters, fast flow of the contrast agent and improved control. Biomed Tech 31:195–200.
DOI: doi.org/10.1515/bmte.1986.31.9.195
7.
7. Byrne RA, Stone GW, Ormiston J, Kastrati A (2017) Coronary balloon angioplasty, stents, and scaffolds. Lancet 390:781–792.
DOI: doi.org/10.1016/s0140-6736(17)31927-x
8.
8. Byrne RA, Joner M, Kastrati A (2015) Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 36:3320–3331
DOI: doi.org/10.1093/eurheartj/ehv511
9.
9. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after trans- luminal angioplasty. N Engl J Med 316:701–706
DOI: doi.org/10.1056/nejm198703193161201
10.
10. Sigwart U (1995) Non-surgical myocardial reduction for hyper- trophic obstructive cardiomyopathy. Lancet 346:211–214.
DOI: doi.org/10.1016/s0140-6736(95)91267-3
11.
11. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al (1994) A comparison of balloon-expanda- ble-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489–495.
DOI: doi.org/10.1056/nejm199408253310801
12.
12. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496–501.
DOI: doi.org/10.1056/nejm199408253310802
13.
13. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Had- amitzky M et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089.
DOI: doi.org/10.1056/nejm199604253341702
14.
14. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J et al (2000) Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 50:290–297.
DOI: doi.org/10.1002/1522-726x(200007)50:3<290::aid-ccd5>3.0.co;2-w
15.
15. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL et al (2011) Stent thrombo- genicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123:1400–1409.
DOI: doi.org/10.1161/circulationaha.110.003210
16.
16. Simon C, Palmaz JC, Sprague EA (2000) Influence of topography on endothelialization of stents: clues for new designs. J Long Term Effects Med Implants 10:143–151.
DOI: doi.org/10.1615/jlongtermeffmedimplants.v10.i12.120
17.
17. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neu- mann FJ et al (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STE- REO) trial. Circulation 103:2816–2821.
DOI: doi.org/10.1161/01.cir.103.23.2816
18.
18. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al (2003) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283–1288.
DOI: doi.org/10.1016/s0735-1097(03)00119-0
19.
19. Schulz S, Mehilli J, Schomig A, Kastrati A (2010) ISAR-a story of trials with impact on practice. Circ J 74:1771–1778.
DOI: doi.org/10.1253/circj.cj-10-0738
20.
20. Palmaz JC, Benson A, Sprague EA (1999) Influence of surface topography on endothelialization of intravascular metallic mate- rial. J Vasc Interv Radiol 10:439–444.
DOI: doi.org/10.1016/s1051-0443(99)70063-1
21.
21. Nakayama Y, Nishi S, Ishibashi-Ueda H, Matsuda T (2000) Surface microarchitectural design in biomedical applications: in vivo analysis of tissue ingrowth in excimer laser-directed micropored scaffold for cardiovascular tissue engineering. J Biomed Mater Res 51:520–528.
DOI: doi.org/10.1002/1097-4636(20000905)51:3<520::aid-jbm29>3.0.co;2-a
22.
22. Dibra A, Kastrati A, Mehilli J, Pache J, von Oepen R, Dirsch- inger J et al (2005) Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a rand- omized double-blind controlled trial. Catheter Cardiovasc Interv 65:374–380.
DOI: doi.org/10.1002/ccd.20400
23.
23. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al (2002) A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780.
DOI: doi.org/10.1056/nejmoa012843
24.
24. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT et al (2004) One-year
25.
clinical results with the slow- release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947.
DOI: doi.org/10.1161/01.cir.0000127110.49192.72
26.
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202
DOI: doi.org/10.1016/j.jacc.2006.03.042
27.
26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948
DOI: doi.org/10.1016/s0140-6736(07)61444-5
28.
27. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al (2005) Inhibition of neointima formation by a novel drug- eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25:748–753
DOI: doi.org/10.1161/01.atv.0000157579.52566.ee
29.
28. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzen- staller T et al (2005) Prevention of restenosis by a novel drug- eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26:1475–1481
DOI: doi.org/10.1093/eurheartj/ehi405
30.
29. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O et al (2008) Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29:1975–1982
DOI: doi.org/10.1093/eurheartj/ehn253
31.
30. Desch S, Schloma D, Mobius-Winkler S, Erbs S, Gielen S, Linke A et al (2011) Randomized comparison of a polymer-free siroli- mus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. JACC Cardiovasc Interv 4:452–459
DOI: doi.org/10.1016/j.jcin.2010.11.016
32.
31. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R et al (2009) The pre-clinical assessment of rapamy- cin-eluting, durable polymer-free stent coating concepts. Bioma- terials 30:632–637
DOI: doi.org/10.1016/j.biomaterials.2008.10.005
33.
32. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL et al (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Effi- cacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 30:2441–2449
DOI: doi.org/10.1093/eurheartj/ehp352
34.
33. Kufner S, Byrne RA, Valeskini M, Schulz S, Ibrahim T, Hopp- mann P et al (2016) Five-year outcomes from a trial of three

Tệp

File PDF
Article Views4
Document Views1
Downloads0
Chuyên mục CHUYÊN ĐỀ
Số phát hành Số 84+85 , 2019